June 3, 2019 10:17 AM EDT

Maligned ex-MiMedx chief Petit wants back on the board — wound care company tells shareholders to say no way

Natalie Grover

Reporter

Weeks ago, a 15-month long sweeping internal investigation encompassing more than a million documents, thousands of hours of secret video surveillance — installed under the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Maligned ex-MiMedx chief Petit wants back on the board — wound care company tells shareholders to say no way

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

What Trump's CMS can and can't change with the second round of drug price negotiations

Updated: J&J to buy Intra-Cellular for $14.6B in latest neuroscience bet

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Ozempic makes list for next round of Medicare drug price negotiations

Ma­ligned ex-MiMedx chief Pe­tit wants back on the board — wound care com­pa­ny tells share­hold­ers to say no way

Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Maligned ex-MiMedx chief Petit wants back on the board — wound care company tells shareholders to say no way